Poly(amino acid) Copolymers as a Potential Soluble Drug Delivery System. 1. Pinocytic Uptake and Lysosomal Degradation Measured In Vitro
Source abstract
Abstract
The suitability of poly(amino acid) copolymers as soluble drug- carriers is determined in part by their rate of pinocytic uptake by cells and intracellular degradation. Poly(amino acid) copolymers, poly(GluNa,Tyr) (1:1) or (4:1) and poly(GluNa,Tyr,Ala) (1:1:1) or (6:3:1) were radioiodinated and their rate of uptake and intracellular degradation measured using rat visceral yolk sacs cultured in vitro as a model system. Pinocytic uptake of these poly(amino acid) copolymers was 10-100 times greater than the rate measured for fluid- phase pinocytosis in the yolk sac, and it was dependent on their composition, poly(GluNa,Tyr) (4:1) being captured fastest. Inhibition of tissue association of radioactivity by incubation at 4°C confirmed uptake to be an active process. Intracellular degradation proceeded rapidly in all cases and was similarly related to copolymer amino acid composition. When the 125 I-labelled poly- (amino acid) copolymers were incubated with isolated rat liver lysosomal en zymes they were degraded to yield TCA soluble radioactivity, poly(GluNa, Tyr,Ala) (6:3:1) being degraded most rapidly (completely degraded within 2h) and poly(GluNa,Tyr) (1:1) degraded very slowly. Lysosomal thiol-dependent (cysteine) proteinases were partly responsible for the observed degradation as judged by leupeptin (24μg/ml) inhibition of degradation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Cancer Research Campaign Laboratory Department of Biological Sciences University of Keele Keele, Staffordshire, ST5 5BG, England
References (23)
Show source-provided references
1. Sidman, K.R., A.D. Schwope, W.D. Steber and S.E. Rudolph in Naltrexone Monograph 28. R. E. Willette and G. Barnett, eds. National Institute on Drug Abuse, p. 214 (1980).
2. 10.1073/pnas.75.4.187210.1073/pnas.75.4.1872 ↗
3. 10.1016/0014-5793(75)80409-110.1016/0014-5793(75)80409-1 ↗
4. 10.1016/0168-3659(85)90006-910.1016/0168-3659(85)90006-9 ↗
5. 10.1016/0003-9861(80)90225-810.1016/0003-9861(80)90225-8 ↗
6. Rihova, B. · CRC Critical Reviews in Therapeutic Drug Carrier Systems · 1985 · 1 · 311
7. 10.1083/jcb.64.1.11310.1083/jcb.64.1.113 ↗
8. 10.1083/jcb.64.1.12310.1083/jcb.64.1.123 ↗
9. 10.1016/0304-4165(81)90058-110.1016/0304-4165(81)90058-1 ↗
10. McCormick, L.A. · J Bioactive Comp. Polymers · 1989 · 4 · 24210.1177/088391158900400302 ↗
11. 10.1016/S0021-9258(19)52451-610.1016/S0021-9258(19)52451-6 ↗
12. 10.1016/0304-4165(78)90339-210.1016/0304-4165(78)90339-2 ↗
13. Trouet, A. in Methods in Enzymology Vol. 21. E. Fleischer and L. Pocker , eds. N.Y.Academic Press, p. 323 (1974).10.1016/0076-6879(74)31034-8 ↗
14. 10.1002/macp.1983.02184100510.1002/macp.1983.021841005 ↗
15. 10.1007/3-540-12796-8_1010.1007/3-540-12796-8_10 ↗
16. Duncan, R. in Controlled Drug Delivery. J. R. Robinson and V. H. L. Lee, eds. N.Y.:Marcel Dekker, Inc., p. 582 (1987).
17. 10.1016/0304-4165(84)90320-910.1016/0304-4165(84)90320-9 ↗
18. 10.1016/0304-4165(84)90320-910.1016/0304-4165(84)90320-9 ↗
19. 10.1177/08839115860010010210.1177/088391158600100102 ↗
20. 10.1007/BF0111624010.1007/BF01116240 ↗
21. 10.1042/bj198058110.1042/bj1980581 ↗
22. 10.1016/S0076-6879(81)80043-210.1016/S0076-6879(81)80043-2 ↗
23. 10.1002/macp.1983.02184100610.1002/macp.1983.021841006 ↗